Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026  Preparing to initiate Company's first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates.